News

Some medicines may carry a higher risk of side effects for the lungs than previously thought, IMI research reveals. The drugs studied work well for most, but doctors should monitor patients for side effects.

In a new series of videos released during IMI’s 10th anniversary, IMI project participants from universities, patient groups, SMEs and the pharmaceutical industry explain how they are benefiting from participating in IMI projects and how they think IMI is changing medical research.

In a new series of videos released during IMI’s 10th anniversary, IMI project participants from universities, patient groups, SMEs and the pharmaceutical industry explain how they are benefiting from participating in IMI projects and how they think IMI is changing medical research.

The eTOX project developed innovative strategies and novel software tools to better predict the safety and side effects of new candidate medicines for patients. In an interview, the project leaders explain how the tools developed by the project are already helping pharmaceutical companies make better-informed decisions in their pursuit of developing safer drugs for patients.

Registration is now open for the IMI Stakeholder Forum 2018, which will take place on Wednesday 24 October in Brussels. The theme this year is ’The value of cross-sectoral health research and innovation’.

The IMI Stakeholder Forum 2018 will take place on Wednesday 24 October in Brussels, Belgium. The theme this year is ‘The value of cross-sectoral health research and innovation’, and discussions will focus on the added value of technology convergence to address complex health challenges, especially in those areas where there is huge public health need.

An Antimicrobial Resistance (AMR) Accelerator Programme is part of new IMI Calls for proposals, along with topics on brain disorders, immune-mediated diseases clinical trial design, medicines safety, and blockchain technologies.

At the Euroscience Open Forum conference, a Bulgarian medical start-up demonstrates the potential - and the challenges - of getting health systems to focus on preventing disease, rather than responding when it strikes

Liquid biopsies can help to diagnose cancer in its early stages, and assist clinicians in monitoring the impact of treatment at any point. IMI's CANCER-ID project has validated a series of tests for cancer cells to help develop more effective methods of diagnosis and more personalised treatments for lung and breast cancer - two of the most frequent malignancies in Europe.

‘Radical collaboration’ where multinational companies work together and share data instead of keeping it secret is helping to change the model of the pharmaceutical industry and solve problems more quickly, according to Carlos Moedas, the EU’s commissioner for research, science and innovation, speaking at an IMI 10th anniversary event in Brussels on 27 June.

A new Antimicrobial Resistance (AMR) Accelerator Programme is part of new Calls for proposals under development at IMI. Other topics slated for inclusion in the Calls address brain disorders and immune-mediated diseases.

IMI's WEB-RADR project has developed a mobile app enabling patients and healthcare professionals to more easily report suspected adverse drug reactions. It has also analysed social media to assess drug safety. Both initiatives have shown potential for strengthening the monitoring of medicines.

IMI’s MARCAR project has identified potential biomarkers that could indicate how likely a drug is to cause cancer at an earlier stage of testing than is currently possible, which could save drug companies time and money – and lead to safer drugs reaching patients faster.

An app developed by Google’s AI company saves nurses two hours a day. But so far it is free to use. An independent panel says DeepMind must clarify the business model, a stark illustration that as healthcare AI goes mainstream, the matter of who does what with patient data is coming into sharper focus

It is crucial to incorporate patient perspectives on healthcare innovation and decision making to increase the sustainability of Europe’s healthcare systems. A panel held at the Science|Business annual conference looked at the role Horizon Europe can play in achieving this

Pagination

Jobs

Welcome to Healthy Measures

Healthy Measures is a multi-stakeholder communications platform to mobilise support for better, equitable and effective health delivery across the EU.

The key to that is a sharper focus on patient outcomes – measuring what works, and doesn’t work, in treating patients from one clinic, region and member-state to another. For that, we need more experts – in industry, policy and academia – who help this effort grow across the EU, from one capital to another. Stakeholder groups need mobilising, and interconnecting, across Europe. The old silos in healthcare across Europe need to be dismantled.